<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Assertio Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/assertio-therapeutics-inc</link>
<description>Latest news and press releases for Assertio Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/assertio-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683548eb78dffbe2df0e4085.webp</url>
<title>Assertio Therapeutics Inc</title>
<link>https://6ix.com/company/assertio-therapeutics-inc</link>
</image>
<item>
<title>Assertio and Garda Mutually Agree to Extend Tender Offer Deadline</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-and-garda-mutually-agree-to-extend-tender-offer-deadline</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-and-garda-mutually-agree-to-extend-tender-offer-deadline</guid>
<pubDate>Wed, 29 Apr 2026 20:30:00 GMT</pubDate>
<description>LAKE FOREST, Ill., April 29, 2026--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. ("Garda") to extend the deadline to commence the previously announced tender offer to acquire all outstanding shares of Assertio to May 4, 2026.</description>
</item>
<item>
<title>Assertio Provides Update on Garda Therapeutics Tender Process</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-provides-update-on-garda-therapeutics-tender-process</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-provides-update-on-garda-therapeutics-tender-process</guid>
<pubDate>Tue, 21 Apr 2026 21:00:00 GMT</pubDate>
<description>LAKE FOREST, Ill., April 21, 2026--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today provided an update that Garda Therapeutics, Inc. ("Garda") intends to commence the tender offer to acquire all outstanding shares of Assertio on April 29, 2026 – the day following the expiration of the 20-day "window-shop" period.</description>
</item>
<item>
<title>Assertio Announces Agreement to be Acquired by Garda Therapeutics</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-announces-agreement-to-be-acquired-by-garda-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-announces-agreement-to-be-acquired-by-garda-therapeutics</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>All-Cash Tender Offer of $18 per share – or $125.1 Million – Plus Contingent Value Right Tender Offer Price Represents 34.6% Premium to Unaffected Price and</description>
</item>
<item>
<title>Assertio Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 16 Mar 2026 20:05:00 GMT</pubDate>
<description>LAKE FOREST, Ill, March 16, 2026--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-16-2026</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-16-2026</guid>
<pubDate>Tue, 03 Mar 2026 21:30:00 GMT</pubDate>
<description>LAKE FOREST, Ill., March 03, 2026--Assertio Holdings, Inc. ("Assertio") (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.</description>
</item>
<item>
<title>Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-regains-compliance-211500092</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-regains-compliance-211500092</guid>
<pubDate>Mon, 12 Jan 2026 21:15:00 GMT</pubDate>
<description>LAKE FOREST, Ill., January 12, 2026--Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with all applicable listing requirements.</description>
</item>
<item>
<title>Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-announces-publication-rolvedon-same-184500600</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-announces-publication-rolvedon-same-184500600</guid>
<pubDate>Fri, 09 Jan 2026 18:45:00 GMT</pubDate>
<description>LAKE FOREST, Ill., January 09, 2026--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist.</description>
</item>
<item>
<title>Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-announces-1-213000081</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-announces-1-213000081</guid>
<pubDate>Mon, 22 Dec 2025 21:30:00 GMT</pubDate>
<description>LAKE FOREST, Ill., December 22, 2025--Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the "Certificate of Amendment") on December 19 to implement a one-for-fifteen reverse split of its issued and outstanding common stock (the "Reverse Split").</description>
</item>
<item>
<title>Assertio Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-third-quarter-2025-211300980</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-third-quarter-2025-211300980</guid>
<pubDate>Mon, 10 Nov 2025 21:13:00 GMT</pubDate>
<description>LAKE FOREST, Ill., November 10, 2025--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Assertio Announces Leadership Transition</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-announces-leadership-transition-131500961</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-announces-leadership-transition-131500961</guid>
<pubDate>Tue, 28 Oct 2025 13:15:00 GMT</pubDate>
<description>Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that its Board of Directors (the “Board”) has appointed director Mark L. Reisenauer as the Company’s Chief Executive Officer (“CEO”),</description>
</item>
<item>
<title>Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-presents-first-ever-real-130000439</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-presents-first-ever-real-130000439</guid>
<pubDate>Mon, 15 Sep 2025 13:00:00 GMT</pubDate>
<description>New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness and real-world data with oral film formulation of clobazamNew data presented during poster session at 150th Annual Meeting of the American Neurological AssociationSYMPAZAN is the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with LGS in patients two</description>
</item>
<item>
<title>Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-present-data-real-world-113000521</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-present-data-real-world-113000521</guid>
<pubDate>Wed, 10 Sep 2025 11:30:00 GMT</pubDate>
<description>Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is now available on ANA2025 website LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products desi</description>
</item>
<item>
<title>Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-participate-hc-wainwright-lake-121500369</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-participate-hc-wainwright-lake-121500369</guid>
<pubDate>Wed, 03 Sep 2025 12:15:00 GMT</pubDate>
<description>LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings at two investor conferences in New York City during September 2025. Company management will host investor meetings at the HC Wainwright Conference on Wednesday, September 10, 2025, taking place at the Lotte New York Palace Hotel. Investors can register and request meetings via their HC Wainwright repre</description>
</item>
<item>
<title>Assertio Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-second-quarter-2025-200500911</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-second-quarter-2025-200500911</guid>
<pubDate>Mon, 11 Aug 2025 20:05:00 GMT</pubDate>
<description>Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the second quarter</description>
</item>
<item>
<title>Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-report-second-123000232</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-report-second-123000232</guid>
<pubDate>Tue, 05 Aug 2025 12:30:00 GMT</pubDate>
<description>LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release second quarter 2025 financial results on Monday, August 11, 2025, after the market close. Additionally, Assertio’s management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide business updates on the Company’s 2025 strategic plans. To access the live webcast, conference call inf</description>
</item>
<item>
<title>Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-participate-alliance-global-partners-201000611</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-participate-alliance-global-partners-201000611</guid>
<pubDate>Mon, 19 May 2025 20:10:00 GMT</pubDate>
<description>LAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O’Grady, Chief Executive Officer, will present at the virtual Alliance Global Partners Healthcare Company Showcase, taking place Wednesday, May 21, 2025. Mr. O’Grady’s fireside chat will be webcast live at 11:20 a.m. ET. To join the event, please register at https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw#/registration, or visit</description>
</item>
<item>
<title>Assertio Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-first-quarter-2025-200100363</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-first-quarter-2025-200100363</guid>
<pubDate>Mon, 12 May 2025 20:01:00 GMT</pubDate>
<description>First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results</description>
</item>
<item>
<title>Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-report-first-121500149</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-holdings-inc-report-first-121500149</guid>
<pubDate>Mon, 05 May 2025 12:15:00 GMT</pubDate>
<description>LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio’s management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company’s 2025 strategic plans. To access the live webcast, conference call information, and other materi</description>
</item>
<item>
<title>Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-participate-iaccess-alpha-virtual-131000098</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-participate-iaccess-alpha-virtual-131000098</guid>
<pubDate>Thu, 20 Mar 2025 13:10:00 GMT</pubDate>
<description>LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O’Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring Investment Conference taking place virtually March 25-26, 2025. The Company will present at 1:30 pm Eastern Time on Tuesday, March 25, 2025. To join the presentation, please visit the webcast available online at https://investor.assertiotx.com/. Additionally, in</description>
</item>
<item>
<title>Assertio Reports Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-fourth-quarter-full-200500181</link>
<guid isPermaLink="true">https://6ix.com/company/assertio-therapeutics-inc/news/assertio-reports-fourth-quarter-full-200500181</guid>
<pubDate>Wed, 12 Mar 2025 20:05:00 GMT</pubDate>
<description>Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024. Said Bre</description>
</item>
</channel>
</rss>